Endpoint, identity, and multi-domain attacks are dominating the enterprise threatscape today, fueled by new tradecraft invented using gen AI.
GlobalData on MSN14h
Genentech’s Itovebi combo hits overall survival endpoint in HER2- breast cancerThe Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback